# Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

> **NCT04892498** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Soochow University** · enrollment: 66 (estimated)

## Conditions studied

- Advanced Refractory Solid Tumors

## Interventions

- **RADIATION:** Hypofractionated radiotherapy
- **DRUG:** PD-1 inhibitor
- **DRUG:** GM-CSF
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT04892498
- **Lead sponsor:** Second Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-30
- **Primary completion:** 2023-08
- **Final completion:** 2024-08
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892498, "Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04892498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*